⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CPRX News
Catalyst Pharmaceutical Inc.
Catalyst Pharmaceuticals Reports Record Fourth Quarter and Record Full Year 2025 Financial Results and Provides 2026 Financial Guidance
globenewswire.com
CPRX
Catalyst Pharmaceuticals to Participate in the Barclays 28th Annual Global Healthcare Conference
globenewswire.com
CPRX
Catalyst Pharmaceuticals to Report Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026
globenewswire.com
CPRX
Santhera Receives Swissmedic Approval of AGAMREE® (Vamorolone) for the Treatment of Duchenne Muscular Dystrophy
globenewswire.com
CPRX
Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2026 List of America's Most Successful Small-Cap Companies
globenewswire.com
CPRX
Nxera Pharma Licenses Japan and Select Asia-Pacific Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals
globenewswire.com
CPRX
CorePlus Collaborates with AIxMED Providing 100% QC on Bladder Cancer Detection with AI
prnewswire.com
CPRX
The University of Notre Dame and Catalyst Pharmaceuticals Host Inaugural Catalyst Advocacy Scholars Summit (CASS)
globenewswire.com
CPRX
Catalyst Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference
globenewswire.com
CPRX
Warum transparente, vergleichbare und zuverlässige Sicherheitstests wichtig sind: AV-Compararives 2025 hebt die Ergebnisse für Enterprise EPR und EDR hervor USA - Deutsch USA - español USA - English USA - English USA - Français
prnewswire.com
CRWD
PANW
FTNT
CPRX
BITF